No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in the pediatric population. Approximately 3000 children in the United States are diagnosed with ALL every year [1]. The survival rate of pediatric ALL has increased from less than 10% to 90% during the past four decades, due to the improvements in the efficacy of multiagent chemotherapy and stratification of treatment intensity [1].

Source: Leukemia Research - March 2, 2018 Category: Hematology Authors: Qingkai Dai, Xiaojuan Liu, Hui Yang, Siqi Guo, Yuefang Wang, Luyun Peng, Lei Ye, Lan Chen, Chunqi Lai, Qi Chen, Ge Zhang, Yongmei Jiang Tags: Research paper Source Type: research